查看購物車
  • Simplified Chinese
  • English
  • Japanese
北美疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）
市場調查報告書
商品編碼
1666306

北美疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）

North America Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 88 Pages | 訂單完成後即時交付

價格

2022年北美疫苗佐劑市值為10.4484億美元，預計到2030年將達到28.6204億美元；預計 2022 年至 2030 年的複合年成長率為 13.4%。

傳染病爆發和流行病的不斷增加推動了北美疫苗佐劑市場的發展

根據世界銀行2023年的報告，細菌、病毒、寄生蟲或真菌疾病都具有傳染性，可以直接在人與人之間或動物與人之間傳播。根據美國國立衛生研究院（NIH）的報告，H1N1流感大流行導致墨西哥旅遊業損失約28億美元，因為在H1N1病毒傳染性的5個月內，遊客人數減少了近100萬人。墨西哥特斯科科州於 2024 年 3 月報告爆發低致病性禽流感 (LPAI) A(H5N2) 疫情，同一州的特馬斯卡拉帕市於 4 月報告爆發另一起疫情。此外，在米卻肯州，一家私人家禽養殖場發現了高致病性禽流感 A(H5N2) 疫情，該疫情於 2024 年 3 月發現。儘管動物流感病毒通常會感染動物，但它們也可以感染人類。人類的感染大多是透過與受感染的動物或受污染環境的密切接觸而感染的。根據原始宿主，甲型流感病毒可分為禽流感、豬流感或其他動物流感病毒。因此，各類傳染病的出現及其伴隨的成本負擔加速了製造商對疫苗和疫苗佐劑的需求。

COVAXIN 是 Bharat Biotech 為對抗新冠疫情而開發的疫苗，使用 Alhydroxiquim-II 作為佐劑。生技公司ViroVax LLC在實驗室中發現並測試了這種佐劑。 Alhydroxiquim-II 的藥理作用是透過淋巴結並激活 TLR7 和 TLR8 細胞受體，這在對抗病毒的免疫反應中發揮著至關重要的作用。 Alhydroxiquim-II是第一個負責活化TLR7和TLR8的佐劑，進而刺激人體的免疫反應。因此，傳染病爆發和大流行的數量不斷增加，導致醫療費用高昂，從而推動了對疫苗佐劑的需求。

北美疫苗佐劑市場概況

北美疫苗佐劑市場分為美國、加拿大和墨西哥。快速的產品核准流程有利於美國疫苗佐劑市場。 2023年5月，葛蘭素史克（GSK）的Arexvy（呼吸道合胞病毒疫苗，佐劑型）疫苗獲得美國食品藥物管理局（FDA）核准，用於預防呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD）。因此，Arexvy 成為全球首個獲得 FDA 批准的老年人 RSV 疫苗。 2022 年 10 月，Novavax, Inc. 的 COVID-19 佐劑疫苗獲得 FDA 緊急使用授權 (EUA)，用於成年患者的加強劑。

北美疫苗佐劑市場收入及 2030 年預測（百萬美元）

北美疫苗佐劑市場區隔

北美疫苗佐劑市場分為佐劑類別、類型和國家。

依佐劑類別，北美疫苗佐劑市場分為礦物鹽佐劑、乳液佐劑、脂質體佐劑等。 2022 年，礦物鹽佐劑佔據北美疫苗佐劑市場的最大佔有率。

根據類型，北美疫苗佐劑市場分為人用疫苗佐劑和獸用疫苗佐劑。 2022 年，人類疫苗佐劑部分佔據了北美疫苗佐劑市場的較大佔有率。

依國家分類，北美疫苗佐劑市場分為美國、加拿大和墨西哥。 2022 年，美國佔據北美疫苗佐劑市場的主導佔有率。

Croda International Plc； CSL有限公司； Dynavax Technologies Corp；葛蘭素史克公司；夏威夷生物技術公司； InvivoGen SAS； Novavax Inc； Phibro 動物健康公司；塞皮克 SA；和 SPI Pharma Inc 是北美疫苗佐劑市場的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美疫苗佐劑市場 - 主要市場動態

  • 北美疫苗佐劑市場 - 主要市場動態
  • 市場促進因素
    • 傳染病爆發和疫情數量不斷增加
    • 獸用疫苗佐劑的核准
  • 市場限制
    • 產品召回和不良影響
  • 市場機會
    • 支持輔助研究的發展和產品發布的合作努力
    • 生物技術和免疫學的進展
  • 未來趨勢
    • 技術進步
  • 促進因素和限制因素的影響：

第 5 章：疫苗佐劑市場 - 北美分析

  • 北美疫苗佐劑市場 - 收入及 2030 年預測
  • 北美疫苗佐劑市場預測與分析

第 6 章：北美疫苗佐劑市場分析 - 按佐劑類別

  • 概述
  • 礦物鹽佐劑
  • 乳化助劑
  • 脂質體佐劑
  • 其他

第 7 章：北美疫苗佐劑市場分析 - 按類型

  • 人類疫苗佐劑
  • 獸用疫苗佐劑

第 8 章：北美疫苗佐劑市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第9章：產業格局

  • 概述
  • 全球疫苗佐劑市場的成長策略
  • 有機發展
    • 概述
  • 無機發展
    • 概述

第10章：公司簡介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Hawaii Biotech Inc
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附錄

Product Code: BMIRE00031087

The North America vaccine adjuvants market was valued at US$ 1,044.84 million in 2022 and is expected to reach US$ 2,862.04 million by 2030; it is estimated to register a CAGR of 13.4% from 2022 to 2030 .

Rising Number of Infectious Disease Outbreaks and Pandemic Fuels North America Vaccine Adjuvants Market

According to the World Bank 2023 report, bacterial, viral, parasite, or fungal diseases can be contagious, spreading directly from person to person or animal to person. As per the National Institute of Health (NIH) report, the H1N1 influenza pandemic resulted in losses of ~US$ 2.8 billion to the Mexican tourism industry, as the footfall of tourists decreased by nearly 1 million over a 5-month window of the contagious spread of H1N1 virus. The Mexican state of Texcoco reported an outbreak of low pathogenicity avian influenza (LPAI) A(H5N2) in March 2024, and Temascalapa municipality in the same state reported another outbreak in April. Additionally, in the state of Michoacan, a private poultry farm detected a high-pathogenicity avian influenza A(H5N2) outbreak that was discovered in March 2024. In 2022, it was reported that both LPAI and HPAI A(H5) subtypes have been found in bird species in Mexico, both recently and in the past. Although they typically infect animals, animal influenza viruses can also infect people. Human infections have mostly been contracted via close contact with animals that are infected or contaminated environments. Influenza A viruses can be categorized as avian influenza, swine influenza, or other animal influenza viruses based on their original host. Therefore, the emergence of various infectious diseases with the associated cost burden accelerates the manufacturers' demand for vaccines and vaccine adjuvants.

COVAXIN, a vaccine developed by Bharat Biotech to fight against the COVID-19 pandemic, uses Alhydroxiquim-II as an adjuvant. The biotech company ViroVax LLC discovered and tested this adjuvant in the laboratory. The pharmacological action of Alhydroxiquim-II is that it travels through lymph nodes and activates TLR7 and TLR8 cellular receptors, which play a vital role in the immune response against viruses. Alhydroxiquim-II is the first adjuvant responsible for activating TLR7 and TLR8, thus stimulating people's immune responses. Therefore, the rising number of infectious disease outbreaks and pandemics, accounting for high healthcare costs, propels the demand for vaccine adjuvants.

North America Vaccine Adjuvants Market Overview

The North America vaccine adjuvants market has been segmented into the US, Canada, and Mexico. Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

North America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Vaccine Adjuvants Market Segmentation

The North America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the North America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the North America vaccine adjuvants market share in 2022.

By type, the North America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of North America vaccine adjuvants market in 2022.

By country, the North America vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the North America vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 North America Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunities
    • 4.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
    • 4.4.2 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -North America Analysis

  • 5.1 North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 North America Vaccine Adjuvants Market Forecast and Analysis

6. North America Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Vaccine Adjuvants Market -Country Analysis

  • 8.1 North America
    • 8.1.1 North America Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 8.1.1.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Seppic SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Hawaii Biotech Inc
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Dynavax Technologies Corp
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 InvivoGen SAS
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Croda International Plc
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Novavax Inc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Phibro Animal Health Corp
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. North America Vaccine Adjuvants Market Segmentation
  • Table 2. North America Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Organic Developments Done by Companies
  • Table 10. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. North America Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. North America Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. North America Vaccine Adjuvants Market by Key Countries - Revenue (2022) US$ Million
  • Figure 13. North America Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 14. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Growth Strategies in the Vaccine Adjuvants Market